论文部分内容阅读
AIM:Bioartificial liver is a hope of supporting liver functionsin acute liver failure patients.Using polysulfon fibers,a newbioartificial liver was developed.The aim of this study wasto show whether this bioartificial liver could support liverfunctions or not.METHODS:Hepatooltes were procured from swine usingSeglen’s methods.The bioartificial liver was constructed bypolysulfon bioreactor and more than 10~(10) hepatocytes.Itwas applied 14 times in 12 patients,who were divided into7 cases of simultaneous HBAL and 5 cases of non-simultaneous HBAL.Each BAL treatment lasted 6 hours.Thegeneral condition of the patients and the biochemical indexeswere studied.RESULTS:After treatment with bioartificial liver,bloodammonia,prothrombin time and total bilirubin showedsignificant decrease.2 days later,blood ammonia still showedimprovment.within one month period,1 case (1/7) insimultaneous group died while in non-simultaneous group2 cases (2/5) died.The difference was significant.Mortalityrate was 25%.CONCLUSION:The constructed bioartificial liver cansupport liver functions in acute liver failure.The simultaneousHBAL is better than non-simultaneous HBAL.
AIM: Bioartificial liver is a hope of supporting liver functionsin acute liver failure patients. Using polysulfon fibers, a newbioartificial liver was developed. The aim of this study wasto show whether this bioartificial liver could support liverfunctions or not. METHODS: Hepatooltes were procured from swine usingSeglen’s methods. The bioartificial liver was constructed by polysylulfon bioreactor and more than 10 ~ (10) hepatocytes. Itwas applied 14 times in 12 patients, who were divided into 7 cases of simultaneous HBAL and 5 cases of non-simultaneous HBAL. Ecol BAL treatment lasted 6 hours. The general condition of the patients and the biochemical indexes were studied .RESULTS: After treatment with bioartificial liver, blood ammonia, prothrombin time and total bilirubin showedsignificant decrease.2 days later, blood ammonia still showedimprovment. with in one month period, 1 case (1 / 7) insimultaneous group died while in non-simultaneous group2 cases (2/5) died. The difference was significant. Fortalityrate was 2 5% .CONCLUSION: The constructed bioartificial liver cansupport liver functions in acute liver failure. Simultaneous HBAL is better than non-simultaneous HBAL.